Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T N Krasnova

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Terapevticheskii Arkhiv|October 9, 1999
[Treatment of bone disorders in renal diseases]A V Kukhtevich, T N Krasnova, A Iu Nikolaev, et al.
Terapevticheskii Arkhiv|January 1, 1989
[Treatment of chronic glomerulonephritis with cytostatics]I E Tareeva, N B Gordovskaia, O P Gladskikh, et al.
Meditsinskaia Tekhnika|August 28, 1998
[The bases for the formalization of syndrome diagnosis for an automatic system of patient management]T N Krasnova, I P Kriukova, A E Krasnova, et al.
Terapevticheskii Arkhiv|September 17, 2016
[Role of polymorphic markers for the genes of hemostasis and platelet receptors in liver fibrosis progression in patients with chronic hepatitis C]E E Starostina, L M Samokhodskaya, T P Rozina, et al.
Terapevticheskii Arkhiv|August 19, 2015
[Prognostic value of renal resistance index in estimating the progression of chronic kidney disease]V E Gazhonova, A S Zykova, A A Chistyakov, et al.
Terapevticheskii Arkhiv|February 1, 2019
The first experience of non-interferon therapy of HCV infection in patients with Wilson-Konovalov's diseaseT P Rozina, T M Ignatova, S V Fastovets, et al.
Terapevticheskii Arkhiv|August 7, 2014
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus]E N Borisov, T N Krasnova, L M Samohodskaia, et al.
Terapevticheskii Arkhiv|April 6, 2005
[Spectrum, incidence and prognostic value of systemic manifestations in chronic hepatitis C of low activity]S Iu Karpov, P E Krel', T n Lopatkina, et al.
Terapevticheskii Arkhiv|October 26, 2022
[Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs]K S Grechukhina, N V Chebotareva, L G Zhukova, et al.
Terapevticheskii Arkhiv|May 29, 2014
[Endothelial dysfunction gene polymorphisms and the rate of liver fibrosis in chronic hepatitis C]O V Taratina, T N Krasnova, L M Samokhodskaia, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Terapevticheskii Arkhiv|October 9, 1999
[Treatment of bone disorders in renal diseases]A V Kukhtevich, T N Krasnova, A Iu Nikolaev, et al.
Terapevticheskii Arkhiv|January 1, 1989
[Treatment of chronic glomerulonephritis with cytostatics]I E Tareeva, N B Gordovskaia, O P Gladskikh, et al.
Meditsinskaia Tekhnika|August 28, 1998
[The bases for the formalization of syndrome diagnosis for an automatic system of patient management]T N Krasnova, I P Kriukova, A E Krasnova, et al.
Terapevticheskii Arkhiv|September 17, 2016
[Role of polymorphic markers for the genes of hemostasis and platelet receptors in liver fibrosis progression in patients with chronic hepatitis C]E E Starostina, L M Samokhodskaya, T P Rozina, et al.
Terapevticheskii Arkhiv|August 19, 2015
[Prognostic value of renal resistance index in estimating the progression of chronic kidney disease]V E Gazhonova, A S Zykova, A A Chistyakov, et al.
Terapevticheskii Arkhiv|February 1, 2019
The first experience of non-interferon therapy of HCV infection in patients with Wilson-Konovalov's diseaseT P Rozina, T M Ignatova, S V Fastovets, et al.
Terapevticheskii Arkhiv|August 7, 2014
[Prognostic value of allelic variants affecting the hemostatic system in the development of antiphospholipid syndrome and kidney lesion in patients with systemic lupus erythematosus]E N Borisov, T N Krasnova, L M Samohodskaia, et al.
Terapevticheskii Arkhiv|April 6, 2005
[Spectrum, incidence and prognostic value of systemic manifestations in chronic hepatitis C of low activity]S Iu Karpov, P E Krel', T n Lopatkina, et al.
Terapevticheskii Arkhiv|October 26, 2022
[Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs]K S Grechukhina, N V Chebotareva, L G Zhukova, et al.
Terapevticheskii Arkhiv|May 29, 2014
[Endothelial dysfunction gene polymorphisms and the rate of liver fibrosis in chronic hepatitis C]O V Taratina, T N Krasnova, L M Samokhodskaia, et al.
Pageof 4